TABLE 3.

Pre- and postchallenge passive transfer of plasma from a Chilean HPS patient to Syrian hamsters

Hamster no.	Antibody		Day 0 PRNT titerc	Challenge virusd	Day of deathe	Terminal bleedf		% Protection
	Sourcea	Dayb injected				PRNT titerg	ELISA titerh	From lethality	From infectioni
125	Normal	−1	<20	ANDV	12	NA	NA	0	0
126			<20	ANDV	10	NA	NA
127			<20	ANDV	11	NA	NA
128			<20	ANDV	12	NA	NA
129	HPS	−1	640	ANDV	−	<20	<100	50	50
130			1,280	ANDV	57	NA	NA
131			640	ANDV	68	NA	NA
132			1,280	ANDV	−	<20	<100
133	HPS	3	<20	ANDV	−	>640	3,200	75	0
134			<20	ANDV	−	160	800
135			<20	ANDV	−	80	800
136			<20	ANDV	12	NA	NA
137	HPS	4	<20	ANDV	12	NA	NA	50	0
138			<20	ANDV	15	NA	NA
139			<20	ANDV	−	320	1,600
140			<20	ANDV	−	320	3,200
141	HPS	5	<20	ANDV	−	>640	6,400	50	0
142			<20	ANDV	−	40	<100
143			<20	ANDV	11	NA	NA
144			<20	ANDV	11	NA	NA
145	HPS	−1	40	None	−	<20	<100	100	100
146			640	None	−	<20	<100
147			320	None	−	<20	<100

^aHPS indicates plasma (PRNT₅₀, 10,240) from a human HPS patient; normal indicates normal human serum.

^bDay antibody injected (1 ml; intraperitoneal) relative to challenge (day 0).

^cNAb titer in hamster serum at time of challenge (PRNT₅₀).

^d2,000 PFU of ANDV (250 LD₅₀) was injected i.m. (ANDV) or no treatment (None).

^e−, animal lived.

^fTerminal bleed on day 98.

^gReciprocal of highest dilution neutralizing 50% of the plaques; NA, not applicable.

^hEndpoint ELISA titer. NA, not applicable.

ⁱProtection from infection (sterile immunity) indicates no detectable antibody response to nucleocapsid in terminal bleed.